Treatment options for hepatic encephalopathy

Pharmacotherapy

Volumn 30, Issue 5 PART 2, 2010, Pages

  Schiano, Thomas D ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Ammonia; Cirrhosis; Clostridium difficile; Hepatic encephalopathy; Lactulose; Neomycin; Nonabsorbable disaccharides; Portosystemic encephalopathy; Rifaximin

Indexed keywords

ANTIBIOTIC AGENT; BENZOIC ACID; DISACCHARIDE; LACTITOL; LACTULOSE; METRONIDAZOLE; NEOMYCIN; PHENYLACETATE SODIUM; PHENYLACETIC ACID DERIVATIVE; PLACEBO; PROBIOTIC AGENT; RIFAXIMIN; UNCLASSIFIED DRUG; ZINC;

ABDOMINAL CRAMP; ACIDIFICATION; ADD ON THERAPY; AMMONIA FORMATION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ASPIRATION; AUDIOMETRY; BACTERIAL OVERGROWTH; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; COGNITION; COLIFORM BACTERIUM; CONTROLLED CLINICAL TRIAL; DEHYDRATION; DETOXIFICATION; DIARRHEA; DRUG ABSORPTION; DRUG BINDING; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXCRETION; DRUG POTENTIATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLATULENCE; FUNGAL COLONIZATION; HEARING IMPAIRMENT; HEPATIC ENCEPHALOPATHY; HOSPITAL COST; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; HYPERNATREMIA; HYPOKALEMIA; INTESTINE FLORA; LIVER CIRRHOSIS; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEPHROTOXICITY; OTOTOXICITY; PRACTICE GUIDELINE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

AMMONIA; ANTI-INFECTIVE AGENTS; CLINICAL TRIALS AS TOPIC; FEMALE; GASTROINTESTINAL AGENTS; HEPATIC ENCEPHALOPATHY; HUMANS; MALE;

EID: 77951727505     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.pt2.16S     Document Type: Review

References (31)

1. Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomized trials. BMJ 2004;328:1046-1051
2. Blei AT, Córdoba J. Hepatic encephalopathy. Am J Gastroenterol 2001;96:1968-1976
3. Munoz SJ. Hepatic encephalopathy. Med Clin N Am 2008;92:795-812.
4. Dhiman RK, Sawhney MS, Chawla YK, Das G, Ram S, Dilawari JB. Efficacy of lactulose in cirrhotic patients with subclinical hepatic encephalopathy. Dig Dis Sci 2000;45: 1549-1552
5. Horsmans Y, Solbreux PM, Daenens C, Desager JP, Geubel AP. Lactulose improves psychometric testing in cirrhotic patients with subclinical encephalopathy. Aliment Pharmacol Ther 1997;11:165-170 (Pubitemid 27067349)
6. Morgan MY, Alonso M, Stanger LC. Lactitol and lactulose for the treatment of subclinical hepatic encephalopathy in cirrhotic patients. A randomized, cross-over study. J Hepatol 1989;8:208-217
7. Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 2007;45:549-559
8. Sharma P, Sharma BC, Puri V, Sarin SK. An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy. Eur J Gastroenterol Hepatol 2008;20:506-511
9. Watanabe A, Sakai T, Sato S, et al. Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy. Hepatology 1997;26:1410-1414 (Pubitemid 27520004)
10. Sharma P, Sharma BC, Sarin SK. Predictors of nonresponse to lactulose for minimal hepatic encephalopathy in patients with cirrhosis. Liver Int 2009;29:1365-1371
11. Apotex Corporation. Lactulose solution USP package insert. Weston, FL; 2003.
12. U.S. Food and Drug Administration. Cumulative list of all products that have received orphan designation. Available from www.fda.gov/downloads/ ForIndustry/DevelopingProductsforRareDiseasesConditions/ HowtoapplyforOrphanProductDesignation/UCM162066.xis. Accessed June 19, 2009.
13. Scarpignato C, Pelosini I. Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. Digestion 2006;73(suppl 1):13-27. (Pubitemid 43296214)
14. Salix Pharmaceuticals, Inc. Xifaxan (rifaximin) package insert. Morrisville, NC; 2008.
15. Neff GW, Kemmer N, Zacharias VC, et al. Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy. Transplant Proc 2006;38:3552-3555
16. Lawrence KR, Klee JA. Rifaximin for the treatment of hepatic encephalopathy. Pharmacotherapy 2008;28:1019-1032
17. Maclayton DO, Eaton-Maxwell A. Rifaximin for treatment of hepatic encephalopathy. Ann Pharmacother 2009;43:77-84.
18. Pedretti G, Calzetti C, Missale G, Fiaccadori F. Rifaximin versus neomycin on hyperammonemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind randomized trial. Ital J Gastroenterol 1991;23:175-178
19. Di Piazza S, Gabriella Filippazzo M, Valenza LM, et al. Rifaximine versus neomycin in the treatment of portosystemic encephalopathy. Ital J Gastroenterol 1991;23:403-407
20. Miglio F, Valpiani D, Rossellini SR, Ferrieri A. Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomized trial. Curr Med Res Opin 1997;13:593-601.
21. Loguercio C, Federico A, De Girolamo V, Ferrieri A, Del Vecchio Blanco C. Cyclic treatment of chronic hepatic encephalopathy with rifaximin. Results of a double-blind clinical study. Minerva Gastroenterol Dietol 2003;49:53-62.
22. Williams R, James OF, Warnes TW, Morgan MY. Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study. Eur J Gastroenterol Hepatol 2000;12:203-208
23. Bass N, Mullen K, Sigal S, et al. Rifaximin is effective in maintaining remission in hepatic encephalopathy: results of a large, randomized, placebo-controlled trial [abstract]. J Hepatol 2009;50(suppl 1):S39.
24. Sanyal A, Bass NM, Teperman L, et al. Chronic rifaximin for maintenance of remission of hepatic encephalopathy: subgroup analysis of a phase 3 trial. Presented at the 44th annual meeting of the European Association for the Study of the Liver, Copenhagen, Denmark, April 23, 2009.
25. Neff G, Leevy C, Merchant K, et al. Rifaximin reduces the risk of hospitalizations in patients with previous episodes of hepatic encephalopathy. Presented at digestive disease week, Chicago, IL, May 31, 2009.
26. Mullen K, Sigal S, Sheikh M, et al. Safety of rifaximin in patients with hepatic encephalopathy: results of a randomized, phase 3, placebo-controlled clinical trial. J Hepatol 2009; 50(suppl 1):S84-5.
27. Batshaw ML, MacArthur RB, Tuchman M. Alternative pathway therapy for urea cycle disorders: twenty years later. J Pediatr 2001;138(suppl):S46-54. (Pubitemid 32099503)
28. Sushma S, Dasarathy S, Tandon RK, Jain S, Gupta S, Bhist MS. Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomized trial. Hepatology 1992;16:138-144
29. Hassanein TI, Tofteng F, Brown RS Jr, et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology 2007;46: 1853-1862
30. Malaguarnera M, Greco F, Barone G, Gargante MP, Malaguarnera M, Toscano MA. Bifidobacterium longum with fructo-oligosaccharide (FOS) treatment in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. Dig Dis Sci 2007;52:3259-3265
31. Bajaj JS, Saeian K, Christensen KM, et al. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. Am J Gastroenterol 2008;103:1707-1715